These NCCN Guidelines Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma (STS) specific to the role of radiation therapy in the management of patients with retroperitoneal/intra-abdominal STS.

Brentuximab vedotin is an antibody-drug conjugate FDA-approved for the treatment of systemic anaplastic large-cell lymphoma (ALCL) that has relapsed after multiagent chemotherapy.

Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family.

These NCCN Guidelines Insights focus on recent recommendations for cervical cancer screening and management of abnormal screening tests.

The NPM-ALK fusion protein is found in ALK+ anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%.

Given the recent expansion of treatment options in advanced melanoma, oncologists now have the opportunity to choose among multiple effective and fairly well-tolerated treatment options.

Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimal management of Merkel cell carcinoma.

This NCCN Guidelines Insights report highlights treatment recommendations and updates specific to the management of patients with advanced non-clear cell carcinoma (non-ccRCC) in the 2014 version of the NCCN Guidelines for Kidney Cancer.

The best treatment strategy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) remains the subject of considerable debate.

Both 5-FU and oxaliplatin have been used as single agents in patients with colon cancer and severe liver dysfunction, but the combination of these drugs has not been yet investigated.